• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Scilex seeks EU nod for ZTlido lidocaine patch

November 14, 2017 By Sarah Faulkner

Scilex PharmaceuticalsSorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals said today that it filed a marketing authorization application seeking approval for its ZTlido lidocaine patch.

The San Diego, Calif.-based company said it is pursuing a hybrid regulatory pathway with the Medicines and Healthcare Products Regulatory Agency in the U.K., which will serve as the lead review agency. The company also plans to file for review in other countries, including Germany, France, Spain, Italy and Ireland.

Scilex said it expects to hear back about its marketing authorization application in the fourth quarter of 2018, since the review time is 210 days. The company is also reviewing commercial options and potential partnerships for its launch in the E.U., according to Scilex.

In September, Scilex said that the FDA received the resubmitted version of a new drug application for ZTlido. The FDA is slated to finish reviewing the company’s NDA by February 28th next year.

If the product wins approval by the FDA, the company has said it could be ready for its U.S. commercial launch in 2018. Sorrento also reportedly plans to submit a marketing authorization application for ZTlido in Europe in the fourth quarter of this year.

Sorrento’s anhydrous patch, designed for the relief of pain associated with post-herpetic neuralgia, contains just 36 milligrams of lidocaine, compared to reference products Lidoderm and Versatis, which each have 700 milligrams of the painkiller.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Scilex Pharmaceuticals, Sorrento Therapeutics

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Reader Interactions

Comments

  1. El says

    January 31, 2019 at 2:00 pm

    As a sufferer of Post herpetic neuralgia after shingles; i tried ZTLido. The information said it was designed specifically for after shingles sufferers. Well it did not work. I have been reading all the info put out by the ZTLido, one thing I noticed they tout how effective the adhesion is.!!!!
    Well I trade effective adhesion for effective treatment of pain. Besides not working, it costs a lot of money!!
    Go back to the drawing board.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS